Leerink Partners Maintains Outperform on Travere Therapeutics, Lowers Price Target to $67

Benzinga · 12h ago
Leerink Partners analyst Joseph Schwartz maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and lowers the price target from $78 to $67.